CFO Elaine Sun steps down; Nicole LaBrosse appointed effective Feb 2, 2022

HALOZYME THERAPEUTICS, INC.

Elaine Sun left immediately to pursue another opportunity; separation agreement expected.
Nicole LaBrosse, previously VP Finance and Accounting since 2020, named CFO.
LaBrosse's initial base salary set at $485,500 with 45% bonus target.
LaBrosse has 18+ years of public accounting and corporate finance experience, including at PwC.
CEO Dr. Helen Torley highlighted LaBrosse's internal knowledge and financial skill set.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Elaine Sun

Senior Vice President, Chief Financial Officer

HALO · HALOZYME THERAPEUTICS, INC.

Effective: 2022-02-02
Successor: Nicole LaBrosse
Filed: February 3, 2022, 6:59 PM ET

On February 2, 2022, Halozyme Therapeutics, Inc. (the “Company”) announced that Elaine Sun is stepping down from her position as Senior Vice President, Chief Financial Officer of the Company, effective immediately, to pursue another opportunity.

Appointed

Nicole LaBrosse

Senior Vice President, Chief Financial Officer

HALO · HALOZYME THERAPEUTICS, INC.

Effective: 2022-02-02
Filed: February 3, 2022, 6:59 PM ET

On February 2, 2022, Nicole LaBrosse was appointed as Senior Vice President, Chief Financial Officer of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Elaine Sun departed as Senior Vice President, Chief Financial Officer at HALOZYME THERAPEUTICS, INC..

Action: stepped down
Role: Senior Vice President, Chief Financial Officer

Exact text from the filing

On February 2, 2022, Halozyme Therapeutics, Inc. (the “Company”) announced that Elaine Sun is stepping down from her position as Senior Vice President, Chief Financial Officer of the Company, effective immediately, to pursue another opportunity.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Nicole LaBrosse was appointed as Senior Vice President, Chief Financial Officer at HALOZYME THERAPEUTICS, INC..

Action: appointed
Role: Senior Vice President, Chief Financial Officer

Exact text from the filing

On February 2, 2022, Nicole LaBrosse was appointed as Senior Vice President, Chief Financial Officer of the Company, effective immediately.

View on SEC.gov

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-22-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.